Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Prestige Consumer Healthcare (PBH) Operating Income: 2009-2025

Historic Operating Income for Prestige Consumer Healthcare (PBH) over the last 16 years, with Sep 2025 value amounting to $79.7 million.

  • Prestige Consumer Healthcare's Operating Income fell 5.54% to $79.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $331.8 million, marking a year-over-year increase of 1.98%. This contributed to the annual value of $336.8 million for FY2025, which is 1.65% down from last year.
  • According to the latest figures from Q3 2025, Prestige Consumer Healthcare's Operating Income is $79.7 million, which was up 11.03% from $71.8 million recorded in Q2 2025.
  • Over the past 5 years, Prestige Consumer Healthcare's Operating Income peaked at $92.0 million during Q4 2024, and registered a low of -$281.0 million during Q1 2023.
  • Moreover, its 3-year median value for Operating Income was $84.3 million (2024), whereas its average is $50.0 million.
  • In the last 5 years, Prestige Consumer Healthcare's Operating Income plummeted by 462.93% in 2023 and then skyrocketed by 129.24% in 2024.
  • Prestige Consumer Healthcare's Operating Income (Quarterly) stood at $82.6 million in 2021, then increased by 5.56% to $87.2 million in 2022, then decreased by 0.40% to $86.8 million in 2023, then increased by 5.91% to $92.0 million in 2024, then declined by 5.54% to $79.7 million in 2025.
  • Its Operating Income was $79.7 million in Q3 2025, compared to $71.8 million in Q2 2025 and $88.4 million in Q1 2025.